Suppr超能文献

中国轻、重症 COVID-19 患者临床症状差异的 Meta 分析。

Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis.

机构信息

Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Department of Pathology, Anhui Medical University, Hefei, China.

出版信息

Front Public Health. 2021 Jan 14;8:561264. doi: 10.3389/fpubh.2020.561264. eCollection 2020.

Abstract

The prognosis of mild and severe patients has prominent differences during the prevalence of COVID-19, and it will be significant to identify patients' potential risk of progressing to severe cases according to their first clinical presentations. Therefore, we aim to review the clinical symptoms of the COVID-19 epidemic systematically. We searched PubMed, Embase, Web of Science, and CNKI (Chinese Database) for studies about the clinical features of COVID-19 in China from March 18 to April 18. Then we used REVMAN to conduct a meta-analysis. After screening, 20 articles including 3,326 COVID-19 confirmed cases were selected from 142 articles we retrieved at the beginning of our research. We divided all the cases into a severe group (including severe and critically severe patients) and a mild group according to the "Diagnosis and Treatment Protocol for Novel Coronavirus Infection-Induced Pneumonia" version 4 (trial). Of all the initial symptoms (including fever, cough, abdominal pain, anorexia, chest tightness, diarrhea, dyspnea, expectoration, fatigue, headache, hemoptysis, myalgia, nausea or vomiting, and pharyngalgia) we studied, we found that cough (odds ratio [OR] = 1.4, 95% confidence interval [CI]: 1.2-1.7; < 0.001), fever (OR = 1.5, 95% CI: 1.2-1.9; < 0.001), dyspnea (OR = 6.2, 95% CI: 3.6-10.6; < 0.001), diarrhea (OR = 2.6, 95% CI: 1.3-4.9; < 0.001), fatigue (OR = 2.1, 95% CI: 1.3-3.3; < 0.01), expectoration (OR = 1.7, 95% CI: 1.2-2.6; < 0.01), myalgia (OR = 1.6, 95% CI: 0.8-3.1; < 0.001), hemoptysis (OR = 4.0, 95% CI: 1.5-11.3; < 0.001), abdominal pain (OR = 7.5, 95% CI: 2.4-23.4; < 0.001), and anorexia (OR = 2.8, 95% CI: 1.5-5.1; < 0.001) had a different distribution in two groups and were statistically significant ( < 0.05). COVID-19 patients whose initial manifestation is dyspnea, hemoptysis, anorexia, diarrhea, or fatigue, especially abdominal pain should be closely monitored to prevent disease deterioration.

摘要

新型冠状病毒肺炎(COVID-19)患者的轻症和重症预后存在显著差异,根据患者的首发临床表现识别其向重症发展的潜在风险具有重要意义。因此,我们旨在系统地回顾 COVID-19 流行期间的临床症状。我们检索了 3 月 18 日至 4 月 18 日期间中国发表的关于 COVID-19 临床特征的 PubMed、Embase、Web of Science 和中国知网(CNKI)数据库。然后使用 REVMAN 进行荟萃分析。经过筛选,我们从最初检索到的 142 篇文章中选择了 20 篇文章,其中包括 3326 例 COVID-19 确诊病例。我们根据“新型冠状病毒感染的肺炎诊疗方案(试行第四版)”将所有病例分为重症组(包括重症和危重症患者)和轻症组。在我们研究的所有初始症状(包括发热、咳嗽、腹痛、食欲不振、胸闷、腹泻、呼吸困难、咳痰、乏力、头痛、咯血、肌痛、恶心或呕吐、咽痛)中,我们发现咳嗽(比值比[OR] = 1.4,95%置信区间[CI]:1.2-1.7;<0.001)、发热(OR = 1.5,95% CI:1.2-1.9;<0.001)、呼吸困难(OR = 6.2,95% CI:3.6-10.6;<0.001)、腹泻(OR = 2.6,95% CI:1.3-4.9;<0.001)、乏力(OR = 2.1,95% CI:1.3-3.3;<0.01)、咳痰(OR = 1.7,95% CI:1.2-2.6;<0.01)、肌痛(OR = 1.6,95% CI:0.8-3.1;<0.001)、咯血(OR = 4.0,95% CI:1.5-11.3;<0.001)、腹痛(OR = 7.5,95% CI:2.4-23.4;<0.001)和食欲不振(OR = 2.8,95% CI:1.5-5.1;<0.001)在两组之间的分布不同,具有统计学意义(<0.05)。COVID-19 患者首发表现为呼吸困难、咯血、食欲不振、腹泻或乏力,尤其是腹痛者,应密切监测,防止病情恶化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6421/7841395/cafd3347d373/fpubh-08-561264-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验